People choosing to take GLP-1s are being accused of taking a shortcut to weight loss, Dr Yoni Freedhoff argues that this stigma may fade as obesity gains recognition as a chronic disease.
A viral report claims GLP-1 social media content is fueling teen eating disorders. Dr Yoni Freedhoff checked the literature and found that the data tell a different story.
A new GLP-1 consensus guideline pushes an idealized, interprofessional model—when a bare-bones standard could empower more clinicians to prescribe safely.
Does the new generation of weight-loss drugs mark the end for weight-loss diet researchers, fat-acceptance entrepreneurs, and others? Yoni Freedhoff, MD, thinks it does.
Two recent developments may potentially increase GLP-1 coverage for more patients with obesity. The lack of coverage may be another failure of recognizing obesity as a chronic disease.
Yoni Freedhoff, MD, reviews the new book 'Food Intelligence,' which details the impact of food on nutrition, biochemistry, metabolism, and health.
Many patients inquire about the risk of suicidal ideation with GLP-1s, writes Yoni Freedhoff, MD. Rather than increasing the risk, he has found they actually decrease it.
Cancer prevention guidelines and studies fail to mention weight loss medications and surgeries, and their ability to decrease risk. Is this another form of weight bias?
